PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

PharmaTher Holdings Ltd. (OTCQB: PHRRF) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Fabio Chianelli will present updates on the company’s FDA Phase 2 clinical studies involving ketamine for conditions like Parkinson’s disease and treatment-resistant depression. The firm is also developing microneedle patches for psychedelic delivery. This presentation will be available to registered attendees for on-demand viewing starting 7:00 AM EST on September 13.

• To provide an update on PharmaTher’s product pipeline and upcoming milestones on its FDA Phase 2 clinical studies and microneedle patch programs involving ketamine and psychedelics
  

TORONTO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce its participation in the H.C. Wainwright 23^rd Annual Global Investment Conference (“the Conference”), taking place virtually on September 13-15, 2021.

PharmaTher’s CEO and Chairman, Fabio Chianelli, will discuss the Company's product pipeline and upcoming milestones, including its FDA Phase 2 clinical study programs with ketamine for Parkinson’s disease, treatment-resistant depression and amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s Disease”). Also, the Company’s microneedle patch programs with ketamine, KETABET™ and psychedelics will be discussed.
      
The presentation will be available to registered Conference attendees for on-demand viewing beginning at 7:00 AM EST on September 13.

Qualified investors can learn more about the Conference and register to schedule a one-on-one meeting with PharmaTher’s management here.

About PharmaTher Holdings Ltd.

​PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelics biotech company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics, such as ketamine, to treat mental health, neurological and pain disorders.  PharmaTher is currently conducting an FDA approved phase 2 clinical study with ketamine to treat Parkinson’s disease and is developing novel microneedle patches for the intradermal delivery of psychedelics.
​
Learn more at: PharmaTher.com and follow us on Twitter and LinkedIn.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "potential", "aim" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the "Company") current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the period of May 31, 2021 ("MD&A"), dated September 7, 2021, which is available on the Company's profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

FAQ

What is PharmaTher Holdings' upcoming event on September 13-15, 2021?

PharmaTher Holdings Ltd. will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, discussing its product pipeline and clinical studies.

What clinical studies will PharmaTher discuss at the conference?

PharmaTher will discuss its FDA Phase 2 clinical studies on ketamine for Parkinson's disease, treatment-resistant depression, and ALS.

What is PharmaTher's stock symbol?

PharmaTher Holdings trades under the stock symbol PHRRF on the OTCQB.

What new developments will PharmaTher present at the conference?

PharmaTher will present updates on its microneedle patch programs for the delivery of ketamine and psychedelics.

When will PharmaTher's conference presentation be available?

The presentation will be available for on-demand viewing starting at 7:00 AM EST on September 13, 2021.